No Data
Express News | Instil Bio Inc - Plans U.S. Trial of Syn-2510/Imm2510 in 2H 2025
Express News | Instil Bio Inc - Initial Clinical Data From 1L Advanced Nsclc Trial in China Expected 2H 2025
Express News | Instil Bio Announces Clinical Progress in China for Imm2510/Syn-2510, a Clinical-Stage Pd-L1Xvegf Bispecific Antibody
ImmuneOnco Biopharmaceuticals' Phase Ib/II Cancer Drug Clinical Study Administers Dose on First Patient
IMMUNEONCO-B (01541.HK): The first patient has been dosed in the Phase IB/II clinical trial of IMM2510 combined with chemotherapy for first-line treatment of NSCLC.
On January 13, Gelonghui announced that IMMUNEONCO-B (01541.HK) has successfully completed the first patient dosing in the Ib/II phase clinical trial of IMM2510 combined with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC). After the safety introduction period, the company plans to recruit first-line patients for the aforementioned clinical trial, expecting to release preliminary clinical data as early as the second half of 2025, including data from first-line NSCLC patients. Clinical data from the dose escalation study of IMM2510 Phase I shows encouraging signs of efficacy: several late-stage solid tumor patients who had failed multiple therapies have received treatment.
Hong Kong stock market activity | IMMUNEONCO-B (01541) rose nearly 15% in the morning, planning to sell Shanghai industrial land for 98.19 million yuan, which will help strengthen the company's Cash / Money Market.
IMMUNEONCO-B (01541) rose nearly 15% in the early session. As of the time of writing, it is up 14.47%, priced at HKD 5.38, with a trading volume of HKD 96.8599 million.
